US equities |
NVDA $204.64 ▼-4.22% INTC $65.76 ▼-28.58% MU $884.74 ▼-5.30% AMZN $240.35 ▼-1.41% AAPL $344.63 ▼-1.23% SNDK $1,150.89 ▼-13.47% AMD $504.80 ▼-10.88% MSFT $521.91 ▼-1.55%
FinancialContent

Axogen, Inc. - Common Stock (NQ:AXGN)

49.37 -0.26 (-0.52%)
Delayed Quote Updated: 4:00 PM EDT, Oct 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million ↗
This healthcare firm develops nerve repair solutions for hospitals and specialists in the U.S. and select global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axogen (AXGN) Q2 2025 Earnings Transcript ↗
Axogen (AXGN) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
From Axogen, Inc.
Via GlobeNewswire
Axogen Inc (NASDAQ:AXGN) Reports Q4 2025 Revenue Growth but Misses Profit Estimates ↗
Via Chartmill
AXOGEN INC (NASDAQ:AXGN) Fits the Minervini Trend Template with Strong Growth Momentum ↗
Via Chartmill
News headline image
Earnings Scheduled For October 29, 2025 ↗
 
Via Benzinga
News headline image
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know ↗
This surgical solutions provider for nerve repair reported a notable insider sale amid a year of strong share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth ↗
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axogen (AXGN) Q4 2025 Earnings Call Transcript ↗
Axogen (AXGN) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock ↗
This healthcare firm delivers surgical solutions for peripheral nerve repair, targeting specialized surgeons across U.S. and global markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axogen, Inc. Reports Fourth Quarter and Full-Year 2025 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces Proposed Public Offering of Common Stock
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen CEO Axed 25,000 Shares From His Direct Holdings ↗
The CEO of this innovative nerve regeneration company sold thousands of shares in December 2025, among multiple other insiders at the company who sold shares to close out that year. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
Gapping stocks in Thursday's session ↗
The market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
News headline image
AXGN Stock Rises Pre-Market After FDA Approves Nerve Repair Graft ↗
Axogen’s Avance is an acellular nerve scaffold for the treatment of adult and pediatric patients aged a month or older with sensory, mixed, and motor peripheral nerve discontinuities. 
Via Stocktwits
Topics Government
News headline image
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
From Axogen, Inc.
Via GlobeNewswire
News headline image
Keep an eye on the top gainers and losers in Wednesday's session. ↗
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Caterpillar Posts Upbeat Q3 Results, Joins United Therapeutics, Centene, Fortive And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Axogen Inc (NASDAQ:AXGN) Surges on Strong Q3 2025 Earnings Beat and Raised Guidance ↗
Axogen (AXGN) stock surged after Q3 2025 earnings beat estimates. Revenue grew 23.5% to $60.1M, while adjusted EPS of $0.12 crushed forecasts. The company also raised its full-year guidance. 
Via Chartmill
Topics Earnings
News headline image
Axogen, Inc. Reports Third Quarter 2025 Financial Results
Raises Full Year Revenue Guidance to at Least 19% Growth or $222.8 million 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
From DJS Law Group
Via Business Wire
News headline image
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >